NICE wants more Abilify data
This article was originally published in Scrip
NICE, the HTA institute for England and Wales, says that it needs more information from Bristol-Myers Squibb and Otsuka Pharmaceuticals before it can assess whether or not to recommend NHS uptake of Abilify (aripiprazole) for patients aged between 15 and 17 with schizophrenia.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.